BJL
GTBP icon

Brighton Jones LLC’s GT Biopharma GTBP Stock Holding History

Brighton Jones LLC’s Portfolio GTBP Stock Details GTBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-390
Closed -$21K – 494
2022
Q3 		$21K Hold
390
– – ﹤0.01% 460
2022
Q2 		$35K Buy
390
+23
+6% +$1.74K ﹤0.01% 467
2022
Q1 		$32K Sell
367
-9
-2% -$794 ﹤0.01% 509
2021
Q4 		$34K Buy
+376
New +$56.3K ﹤0.01% 524

Other funds holding GTBP

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BFS
Baskin Financial Services Toronto, Ontario, Canada $1.27B AUM 9.68% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Brighton Jones LLC's GTBP Position: Q4 2022 in Review

Brighton Jones LLC sold out of GT Biopharma (GTBP) in Q4 2022, closing a stake of 390 shares — an estimated $21K sold.

Brighton Jones LLC first reported a position in GTBP in Q4 2021 and held it in 4 quarters. The position peaked at $35K in Q2 2022. 36 funds tracked by Wall St. Rank hold GTBP as of Q4 2022.

  • Brighton Jones LLC reported no remaining GT Biopharma position as of Q4 2022 after selling out during the quarter.
  • Brighton Jones LLC sold 390 GT Biopharma shares in Q4 2022, an estimated $21K.
  • Brighton Jones LLC first reported a position in GT Biopharma in Q4 2021 and held it in 4 quarters.
  • Brighton Jones LLC's GT Biopharma position peaked at $35K in Q2 2022.
  • 36 funds tracked by Wall St. Rank held GT Biopharma as of Q4 2022.

Based on Brighton Jones LLC's 13F filing for Q4 2022, filed 3 Feb 2023.